VIMPAT® (lacosamide) Patent Survives IPR Challenge April 25, 2017 The PTAB upheld the validity of Patent RE38,551 E (“the ’551 patent”), which covers VIMPAT® (lacosamide). See PTAB Litigation Blog by Jones Day, LLP: “Pharmaceutical Compound Nonobvious Absent Evidence Suggesting Specific Modification to Prior Art Compound” IPR2016-00204 Share: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Share on LinkedIn (Opens in new window) LinkedIn Print (Opens in new window) Print
